Kitty Yale

机构：Spero Therapeutics (United States) · ORCID：0000-0002-3813-1626

发表论文 34 篇 · 总被引 2834 次 · h-index 18

代表论文

• Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021 · Nature Medicine · 被引 361)
• Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults (2013 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 307)
• Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 262)
• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025 · New England Journal of Medicine · 被引 124)
• A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis (2022 · JHEP Reports · 被引 107)
• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study (2024 · Clinical Gastroenterology and Hepatology · 被引 96)